Outcomes
REGRESSION, DISEASE, SOLID TUMORS, ONCOLOGY
Regardless of the receipt of durvalumab, the median PFS in all eligible patients was 18.4 months compared to 9.7 months in ineligible patients (hazard ratio [HR] 0.61, 95% confidence interval [CI] 0.39–0.95, log rank Kaplan–Meier curves of progression‐free survival as per the response evaluation criteria in solid tumors, version 1.1, in patients eligible (median 9.7 months) and ineligible (median 18.4 months) for the PACIFIC trial. Hazard ratio 0.61 (95% confidence interval 0.39–0.95), Kaplan–Meier curves of overall survival as per the response evaluation criteria in solid tumors, version 1.1, in patients ineligible (median 26.5 months) and eligible (median 58.7 months for the PACIFIC trial. Hazard ratio 0.47 (95% confidence interval 0.28–0.80), When patients that had progressive disease after chemoradiotherapy regardless of receipt of durvalumab were not analyzed in the survival outcome, median OS remained significantly shorter in all ineligible patients compared to eligible patients (28.4 vs. 58.7 months, HR 0.51, 95% CI 0.28–0.95, log rank In univariate analysis, patients who received less than standard dose radiotherapy had shorter PFS (HR 3.38, 95% CI 1.71–6.68, Univariate Cox proportional hazards regression analysis showing hazard ratios for progression‐free survival and overall survival for different variables in the overall cohort
Multivariable Cox proportional hazards analysis showing hazard ratios for progression‐free survival for Eastern Co‐operative Oncology Group, PACIFIC trial ineligibility, radiotherapy dose, smoking status, and histology in the overall cohort. *Multivariable Cox proportional hazards analysis showing hazard ratios for overall survival for Eastern Co‐operative Oncology Group, PACIFIC trial ineligibility, less than standard dose radiotherapy, smoking status, and histology in the overall cohort. *